Oberg Industries, Inc., a contract manufacturer of complex tooling and precision machined or stamped metal components, is pleased to announce the completion of a successful routine inspection by the U.S. Food and Drug Administration (FDA) at its contract manufacturing sites in Sarver, PA and Freeport PA.
The comprehensive inspection began on Tuesday, April 4 and concluded on Thursday, April 6. Each site was found to be compliant with the principles and guidelines of Current Good Manufacturing Practices (cGMP), and no Form 483 observations were issued.
At the completion of the inspection, David Bonvenuto, President and CEO of Oberg Industries, commented, “We are pleased with the outcome of the FDA Inspection of our two contract manufacturing sites and this is a testimony to Oberg’s commitment to world-class quality and continuous improvement. Our team’s commitment to quality is at the forefront of everything we do to ensure that our products comply with both FDA Regulations and our Customer Partner Requirements.”